peroxisome proliferator-activated receptor (PPAR)insulin resistanceLanifibranor is a pan-PPAR agonist with anti-inflammatory and anti-fibrotic effects under investigation for MASLD/MASH.This phase 2 trial simultaneously examined the effect of lanifibranor on hepatic fat and insulin sensitivity using gold...
PPAR-GammaER stressAim This study sought to evaluate the effects of LDT409, a pan-PPAR partial agonist obtained from the main industrial waste from cashew nut processing, on hepatic remodeling, highlighting energy metabolism and endoplasmic reticulum (ER) stress in high-fructose-fed mice. Methods ...
In M1-polarized THP-1 cells, the reduction in the mRNA expression of inflammatory cytokines was more significant in pan-PPAR-iMSC-EVs than that in iMSC-EVs. In the mouse model of cisplatin-induced AKI, pan-PPAR-iMSC-EVs markedly enhanced renoprotective effects compared to iMSC-EVs. ...
摘要 目的探讨PPAR-α激动剂非诺贝特对氨基核苷嘌呤霉素(PAN)诱导肾小球足细胞损伤的作用及其机制。方法将18只8周龄SD♀大鼠随机分为3组(n=6)。PAN模型组和非诺贝特组1次尾静脉注射PAN 65 g·g-...展开更多 Aim To investigate the function of fenofi-brate on PAN ( puromycin aminonucleoside )-induced ...
Although the antifibrotic effect of pan PPAR was similar to that of PPARγ agonist alone, a significant downregulation of several markers of inflammation was associated with IVA337. Despite its anti-inflammatory and antifibrotic properties, IVA337 did not interfere with wound closure. In vitro ...
尽管在许多肾脏疾病中,PPAR-α都表现出保护作用,但是其在氨基核苷嘌呤霉素(PAN)诱导的大鼠肾小球足细胞损伤中的作用报道较少。因此,我们拟通过建立PAN大鼠肾小球足细胞损伤模型,以尿蛋白水平的上升和足细胞损伤标志物desmin的表达上调作为成模型标准,通过PPAR-α特异性激动剂非诺贝特予以治疗,探索PPAR-α激动剂非诺贝特...
PPAR-α激动剂对PAN诱导肾小球足细胞损伤的保护作用 许俊铭;潘方瑜;刘源;岳晓阳;邹军 【期刊名称】《中国药理学通报》 【年(卷),期】2014(000)010 【摘要】Aim To investigate the function of fenofi-brate on PAN ( puromycin aminonucleoside )-induced podocyte injury. Methods SD female rats of 18-week...
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017 Nov;76(11):1931-1940. Disclosure of Interests Chandran Nagaraj: None declared, Neha Sharma: None declared, Bence Nagy: None declared, Jean-Louis Junien Shareholder of: shareholder ...
Due to the undesirable side-effects, many PPAR agonists including PPARα/γ and PPARβ/γ dual agonists are stopped by US FDA in the clinical trials. An alternative strategy is to design novel pan-agonist that can simultaneously activate PPARα, PPARβ and PPARγ...
Cx-43基因蛋白水平明显增加,线粒体凋亡通路和TGF-β/Smad通路转录水平显著上调.非诺贝特处理能够显著降低PAN引起的尿蛋白,改善PAN对足细胞的损伤作用;显著抑制凋亡通路的转录活性,减少Cx-43的转录和表达,降低骨架蛋白和裂隙膜蛋白的转录活性.结论:PPAR-a的激活能够改善PAN诱导的肾小球足细胞损伤,其作用机制与抑制凋亡...